Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Myeloid 3Gastrointestinal 3Thoracic 1Other hematologic neoplasm 1NET 1Lymphoid 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 117Gastro-enteropancreatic neuroendocrine tumor 21Neoplasms 20Carcinoid Tumor 17Colorectal Neoplasms 13Carcinoma, Neuroendocrine 11Neoplasm Metastasis 10Carcinoma 10Lung Neoplasms 9Small Cell Lung Carcinoma 8Prostatic Neoplasms 8Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 8Sarcoma 7Pancreatic Neoplasms 7Carcinoma, Hepatocellular 7Adenoma, Islet Cell 7Stomach Neoplasms 6Serotonin Syndrome 6Pheochromocytoma 6Melanoma 6Head and Neck Neoplasms 6Digestive System Neoplasms 6Cholangiocarcinoma 6Thyroid Neoplasms 5Paraganglioma 5Ovarian Neoplasms 5Gastroenteropancreatic Neuroendocrine Tumors 5Colonic Neoplasms 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Piebaldism × NET × Clear all
NCT06805825 2025-09-23

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

Novelty Nobility, Inc.

Phase 1 Recruiting
67 enrolled
DermatologicEndocrineGastrointestinalGenitourinaryNETSarcomaThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Carcinoma, Adenoid Cystic, Piebaldism, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡